GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Inventories, Finished Goods

Oruka Therapeutics (FRA:HQ1) Inventories, Finished Goods : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Inventories, Finished Goods?

Oruka Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Oruka Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Inventories, Finished Goods Chart

Oruka Therapeutics Annual Data
Trend Dec24
Inventories, Finished Goods
-

Oruka Therapeutics Semi-Annual Data
Dec24
Inventories, Finished Goods -

Oruka Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Inventories, Finished Goods
Comparable Companies
VSTM RAPP ALT ORIC TECX ZVRA ERAS TSHA MAZE SANA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
ORKA:USA
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines